Background: Fingolimod is a widely used treatment for highly active relapsing-remitting multiple sclerosis. Objectives: To describe the case of a 27-year-old patient treated for more than 2 years by Fingolimod, who presented hemiplegia and speech disturbances associated with extensive white matter lesions on brain magnetic resonance imaging (MRI). Methods: Case study. Results: Although initial presentation questioned the possibility of progressive multifocal leukoencephalopathy, final diagnosis was multiple sclerosis (MS) relapse. Appropriate treatment resulted in clinical and radiological improvement. Conclusion: Severe MS relapses under Fingolimod have been reported, but late onset after treatment initiation and extensive subcortical topography is unusual and represents a diagnostic challenge.
Introduction
Fingolimod (Gilenya ® , Fg), the first-in-class orally compound that has shown efficacy in clinical trials for the treatment of relapsing-remitting multiple sclerosis (RRMS), is used as a first-line therapy for highly active RRMS or as a second-line therapy. 1 Fg is a sphingosine 1-phosphate (S1P) partial agonist that downregulates expression of S1P receptors on lymphocytes, preventing their recirculation from lymph nodes. Its administration results in a decrease in circulating T and B lymphocytes. Tumefactive multiple sclerosis (MS) lesions have been described under Fg, leading to the consideration that it may have a paradoxical effect in some cases. 2 Moreover, few cases of progressive multifocal leukoencephalopathy (PML) have been reported in association with Fg, highlighting the need for cautious monitoring.
We report the case of a 27-year-old female who presented a severe MS relapse associated with two atypical extensive subcortical lesions mimicking PML, occurring under Fg, 24 months after treatment onset.
Case report
A 27-year-old female with an 8-year history of RRMS was admitted in our department in July 2015. She was diagnosed with MS in 2008 after two different clinical relapses (right sensitive disorders in September 2007 then optic neuritis in February 2008). Brain magnetic resonance imaging (MRI) revealed white matter encephalic lesions (Figure 1 (a)-(d)). McDonald criteria were fulfilled. She was first treated with glatiramer acetate, which was discontinued in October 2011 during a pregnancy and resumed 1 month after delivery. Because of persisting clinical relapses and radiological activity, Fg was started in June 2013. After 1 month, she reported a mild relapse, then remained asymptomatic (Expanded Disability Status Scale (EDSS): 0). In July 2015, more than 2 years after Fg onset, she developed, within a few days, a right-sided hemiplegia with severe speech disturbance. Brain MRI (performed 7 days after symptom-onset) revealed two new large subcortical white matter lesions (Figure 1 (e)-(l)). The radiological aspect of the lesions with large size, irregular borders, and partial involvement of
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U-fibers and their occurrence under Fg were atypical for MS lesions. The presence of a strong peripheral hyperintensity on diffusion weighted imaging (DWI), associated with an apparent diffusion coefficient (ADC) restriction over 40%, and a faint peripheral enhancement after gadolinium injection were suggestive of PML. Fg was immediately stopped. Lymphocyte count was decreased to 560/mm 3 (400/mm 3 in May 2014). Blood John Cunningham Virus (JCV) serology (STRATIFY JCV™ performed by Unilabs) and polymerase chain reaction (PCR) for JCV in cerebrospinal fluid (CSF) (performed by Unilabs with a sensitivity of 10 copies/mL) were negative twice. According to these results, PML hypothesis was ruled out: patient received intravenous methylprednisolone (IVMP) during 10 days with close clinical and radiological monitoring. At day 15, brain MRI revealed an extension of the left subcortical white matter lesion, while ADC restriction was less visible, and areas of contrast enhancement had regressed (Figure 1 (m)-(r)). At day 21, clinical improvement was noticed (EDSS: 3.5). Encephalic lesions were stable but ADC returned to normal values (not shown). In August 2015, she had a new relapse with a cerebellar ataxia, right-sided facial hypesthesia, and left-sided hypesthesia (EDSS: 6.0).
Brain MRI showed a new extensive lesion of the right middle cerebellar peduncle (not shown); the previous lesions were unchanged. She received IVMP and natalizumab (Nz) was initiated in October 2015. She progressively clinically improved, with an EDSS of 3.0 after 6 months of Nz treatment. Follow-up MRI showed a complete regression of DWI hyperintensities and the absence of contrast enhancement ( Figure  1(s)-(x) ).
Discussion
This case shows the complexity to reach a diagnosis in the case of extensive encephalic lesions appearing 2 years after Fg initiation.
Given the severity of the neurological symptoms (hemiplegia and speech disturbance) and the radiological aspect of the lesions (large size, irregular borders, involvement of some U-fibers, peripheral DWI hyperintensity with ADC restriction, and marginal contrast enhancement 3 ), PML was the first hypothesized diagnosis. A total of 18 PML cases were described under Fg, among which 12 cases occurred after natalizumab exposition. Only six cases occurred ; apparent diffusion coefficient maps (i, j); and diffusion-weighted sequences (k, l, q, r, w, x). MRI at D7 shows extensive lesion of left frontoparietal and right parietal white matter, hyperintense on FLAIR with punctate, irregular margins (e, f, yellow arrows), midly hypointense on T1 with a faint peripheral enhancement (g, h, yellow arrows), a strong hyperintensity on DWI (k, l, yellow arrows), and an ADC decrease over 40% (i, j, yellow arrows). MRI at D15 shows extension of FLAIR signal (m, n, with arrowheads in n pointing to partial involvement of subcortical U-fibers) and of DWI hyperintensity (q, r) but regression of contrast enhancement (o, p). MRI at M7 shows complete regression of DWI high signal (w, x) and no contrast enhancement (u, v). without prior immunosuppressive drug; therefore, prescription and follow-up guidelines do not include JCV serology yet. Thus, the unknown previous JCV serology status of our patient reinforced the suspicion for this diagnosis. PML was finally ruled out by the negativity of JCV serology and the JCV-PCR in the CSF. However, these viral results are not immediately available; in addition, a recent PML case has been diagnosed in an MS patient despite a negative JCV serology 2 weeks after the onset of symptoms. 4 Decreased ADC has been described in the periphery of PML lesions; 5 however, it has also been reported in the very early phase of acute MS lesions (up to 66%), especially in the first 7 days (with a maximum of 10 days) after symptom onset. 6 This radiological finding is thus not completely specific of PML.
Severe MS relapses under Fg have been reported in particular situations: (1) during a switch between Nz and Fg, 7 (2) after Fg cessation, as a rebound effect, 8 and (3) during the first 5 months of treatment, which can be equivalent to a lack of efficacy or even questions a paradoxical effect. 2 Hellman et al. 9 reported a case of tumefactive demyelination, beginning 14 months after Fg treatment onset, with a diagnosis of typical demyelination on brain biopsy performed 22 months after Fg initiation. Our case is, to our knowledge, the first report of extensive multifocal and subcortical lesions occurring after 24 months of well-conducted treatment with Fg, distinguishing it from previously reported tumefactive demyelinating lesions occurring early after initiation or interruption of Fg. The long clinical and radiological stability before a spectacular aggressive activity of MS disease questions the physiopathology of such disease "rebound." Although mechanisms involved in such aggressive MS relapses are unknown, the presence of neutralizing antibodies against Fg, in analogy with those described against natalizumab 10 might be hypothesized. This case highlights that (1) severe MS relapse can be revealed by extensive subcortical and multifocal lesions mimicking PML, (2) severe MS relapse can occur after 2 years of well-conducted treatment by Fg, and (3) cautious MRI monitoring might be needed, for MS patients with Fg, even after 2 years of wellconducted and well-tolerated treatment.
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